首页 > 研究生教育 > 博士生导师

 

赵维莅

主任医师,博士生导师

实验血液学研究课题组组长
Email: zhao.weili@yahoo.com

> 研究方向

目前研究重点为:(1) 淋巴瘤生物学特性、临床进展、药物敏感性和预后转归密切相关的分子标志;(2) 针对淋巴瘤关键分子标志及信号途径的特异性靶向治疗药物淋巴瘤多靶点、多元化靶向治疗策略的探索和临床转化。

> 学习经历

1991-1998 上海第二医科大学七年制 研究生/硕士
2001-2003 法国巴黎第七大学 研究生/博士

> 工作简历

1998-2001 上海交通大学附属瑞金医院血液科 主治医师
2004-2008 上海交通大学附属瑞金医院血液科 副主任医师
2005-至今 上海交通大学附属瑞金医院血液科 科副主任
2007-至今 上海血液学研究所 副所长
2008-至今 上海交通大学医学院 博士生导师
2009-至今 上海交通大学附属瑞金医院血液科 教授/主任医师

> 荣誊

2015年 教育部长江特聘教授
2014年 国家杰出青年基金
2014年 国家百千万人才
2014年 上海青年科技英才
2013年 上海市青年五四奖章
2013年 上海市优秀学术带头人
2012年 全国卫生系统先进工作者
2011年 上海市三八红旗手
2010年 上海领军人才

> 近期主要论文

1、Nat Genet. 2015;47(9):1061-6.
Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma.
Jiang L, Gu ZH, Yan ZX, Zhao X, Xie YY, Zhang ZG, Pan CM, Hu Y, Cai CP, Dong Y, Huang JY, Wang L, Shen Y, Meng G, Zhou JF, Hu JD, Wang JF, Liu YH, Yang LH, Zhang F, Wang JM, Wang Z, Peng ZG, Chen FY, Sun ZM, Ding H, Shi JM, Hou J, Yan JS, Shi JY, Xu L, Li Y, Lu J, Zheng Z, Xue W, Zhao WL, Chen Z, Chen SJ.

2、Autophagy. 2015;11(12):2160-71.
Induction of autophagy by valproic acid enhanced lymphoma cell chemosensitivity through HDAC-independent and IP3-mediated PRKAA activation.
Ji MM, Wang L, Zhan Q, Xue W, Zhao Y, Zhao X, Xu PP, Shen Y, Liu H, Janin A, Cheng S, Zhao WL.

3、Blood Cancer J. 2015;5:287.
Dysregulated choline metabolism in T-cell lymphoma: role of choline kinase-α and therapeutic targeting.
Xiong J, Bian J, Wang L, Zhou JY, Wang Y, Zhao Y, Wu LL, Hu JJ, Li B, Chen SJ, Yan C, Zhao WL.

4、Front Med. 2015;9(4):468-77.
Clinical characteristics and prognostic factors of patients with mature T-cell lymphoid malignancies: a single-institution study of 225 cases.
Xue W, Sheng Y, Weng X, Zhu Y, Zhao Y, Xu P, Fei X, Chen X, Wang L, Zhao W.

5、Biomed Res Int. 2015;2015:197241.
MicroRNA181a Is Overexpressed in T-Cell Leukemia/Lymphoma and Related to Chemoresistance.
Yan ZX, Zheng Z, Xue W, Zhao MZ, Fei XC, Wu LL, Huang LM, Leboeuf C, Janin A, Wang L, Zhao WL.

6、World J Surg Oncol. 2015;13:246.
Localized primary gastrointestinal diffuse large B cell lymphoma received a surgical approach: an analysis of prognostic factors and comparison of staging systems in 101 patients from a single institution.
Zhang S, Wang L, Yu D, Shen Y, Cheng S, Zhang L, Qian Y, Shen Z, Li Q, Zhao W.

7、Ann Hematol. 2015;94(2):239-47.
Analysis of prognostic factors and comparison of prognostic scores in peripheral T cell lymphoma, not otherwise specified: a single-institution study of 105 Chinese patients.
Xu P, Yu D, Wang L, Shen Y, Shen Z, Zhao W.

8、Leukemia. 2014;28(4):880-7.
MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma.
Yan ZX, Wu LL, Xue K, Zhang QL, Guo Y, Romero M, Leboeuf C, Janin A, Chen SJ, Wang L, Zhao WL.

9、J Hematol Oncol. 2014;7:88.
c-FLIP is involved in tumor progression of peripheral T-cell lymphoma and targeted by histone deacetylase inhibitors.
Zheng Z, Cheng S, Wu W, Wang L, Zhao Y, Shen Y, Janin A, Zhao WL.

10、J Hematol Oncol. 2014;7:75.
Catechins induced acute promyelocytic leukemia cell apoptosis and triggered PML-RARα oncoprotein degradation.
Zhang L, Chen QS, Xu PP, Qian Y, Wang AH, Xiao D, Zhao Y, Sheng Y, Wen XQ, Zhao WL.

11、PLoS One. 2014;9(2):e89302.
GSTT1 deletion is related to polycyclic aromatic hydrocarbons-induced DNA damage and lymphoma progression.
Yang F, Xiong J, Jia XE, Gu ZH, Shi JY, Zhao Y, Li JM, Chen SJ, Zhao WL.

12、J Hematol Oncol. 2013;6:53.
Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma.
Dong LH, Cheng S, Zheng Z, Wang L, Shen Y, Shen ZX, Chen SJ, Zhao WL.

13、Biomark Res. 2013;1(1):24.
Genetic methylation and lymphoid malignancies: biomarkers of tumor progression and targeted therapy.
Zhao X, Zhang W, Wang L, Zhao WL.

14、Clin Radiol. 2013;68(3):e143-53.
A pooled analysis of MRI in the detection of bone marrow infiltration in patients with malignant lymphoma.
Jiang XX, Yan ZX, Song YY, Zhao WL.

15、Cell Death Dis. 2012;3:e275.
Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy.
Shi WY, Xiao D, Wang L, Dong LH, Yan ZX, Shen ZX, Chen SJ, Chen Y, Zhao WL.

16、Med Oncol. 2012;29(3):2176-82.
Prognostic factors of Chinese patients with T/NK-cell lymphoma: a single institution study of 170 patients.
Xu PP, Wang Y, Shen Y, Wang L, Shen ZX, Zhao WL.

17、Haematologica. 2011;96(6):927-31.
Bevacizumab potentiates chemotherapeutic effect on T-leukemia/lymphoma cells by direct action on tumor endothelial cells.
Wang L, Shi WY, Yang F, Tang W, Gapihan G, Varna M, Shen ZX, Chen SJ, Leboeuf C, Janin A, Zhao WL.

18、Ann Hematol. 2011;90(1):53-8.
Proteasome inhibitor bortezomib targeted tumor-endothelial cell interaction in T-cell leukemia/lymphoma.
Shi WY, Wang L, Xiao D, Yao Y, Yang F, Jiang XX, Leboeuf C, Janin A, Chen SJ, Zhao WL.